Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Thousands register for new hepatitis C drug in Egypt sold at 99 percent discount

On Thursday, Gamal Esmat, member of the Egyptian National Committee on Viral Hepatitis told Aswat Masriya that around 1,7000 people had registered hours after online registration opened on the Health Ministry’s website.

Published
19 September 2014
From
Egyptian Streets
US: How Insurers Are Finding Ways to Shift Costs to the Sick

Health insurance companies are no longer allowed to turn away patients because of their pre-existing conditions or charge them more because of those conditions. But some health policy experts say insurers may be doing so in a more subtle way: by forcing people with a variety of illnesses — including Parkinson’s disease, diabetes and epilepsy — to pay more for their drugs.

Published
18 September 2014
From
New York Times
Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target?

Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.

Published
17 September 2014
From
Infojustice
Access to sofosbuvir in middle-income countries

Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.

Published
17 September 2014
From
I-MAK
Open Letter to President-elect Jean-Claude Juncker on move of medicinal products and health technologies to the portfolio of the Commissioner for internal market and industry

We are writing to express our astonishment and concern regarding your decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market and industry within the new Commission.

Published
17 September 2014
From
EATG
Unique Health Care Challenges for Older Adults with HIV

Dr. Meredith Greene, fellow in the Division of Geriatrics at University of California, San Francisco, has spent her career working out how to integrate HIV services and geriatric care. “Traditionally, those areas haven’t overlapped a lot,” she explains—yet as individuals with HIV live longer with increasingly more effective and tolerable HIV therapies, she recognizes the importance of tailoring medical care services for older HIV-positive adults to their unique medical needs.

Published
17 September 2014
From
BETA blog
Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism

more than three dozen patient advocacy groups say the licensing deals do not go far enough, because the deals excludes many middle-income countries – such as Brazil, China, Turkey, Thailand and Ukraine – where governments and individuals may not be able to afford the Gilead drug. The patient groups are concerned the licenses will preclude the generic drug makers from selling lower-cost versions to those countries and potentially excluding millions of patients with hepatitis C from gaining access to treatment.

Published
16 September 2014
From
Pharmalot
Gilead signs pact with 7 firms for cheap copies of hepatitis C drug

Gilead's licensing agreement with firms including India's Cipla Ltd and Ranbaxy Laboratories Ltd clears the way for the launch of a cheap generic version of the drug in 91 developing countries that make up 54 percent of the total global hepatitis burden.

Published
15 September 2014
From
Reuters
The Enfant Terrible of AIDS Activism Reaches a New Low

Michael Weinstein, president of the AIDS Healthcare Foundation, is many things—professional provocateur; contrarian pariah; enfant terrible of the AIDS activism world. But here’s one thing he is not: a reliable source on any matters relating to HIV/AIDS.

Published
15 September 2014
From
Slate
Gilead to raise price for new hepatitis C drug above $84000

The fixed-dose regimen version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

Published
15 September 2014
From
Reuters
← First12345...442Next →

Filter by country